Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem in pediatric Urea Cycle Disorders
NCT03884959Phase 2Withdrawn
- Sponsor
- HLB Cell
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hepastem in urea cycle disorders (UCD), sponsored by HLB Cell. Primary endpoints: Change of ureagenesis at 6 months, Hemodynamics (measurement of portal vein pressures) at 12 months and 2 more. Planned start Jul 2018; status: withdrawn.
02
Drugs
hepastem
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT03884959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884959.